MedPath

Correlation between clinical features and laboratory parameters in adult patients having atopic dermatitis

Not Applicable
Conditions
Health Condition 1: L209- Atopic dermatitis, unspecified
Registration Number
CTRI/2023/06/053581
Lead Sponsor
Society for eczema Studies
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

(a)Age at presentation equal to or more than 18 years

(b)Active atopic dermatitis diagnosis of which shall be made on 2 grounds

1. Fulfilment of Hanifin and Rajkaâ??s original criteria

2. Expert opinion where 3 independent eczema experts decide unanimously on the diagnosis of adult AD

Exclusion Criteria

(a)Pregnancy and lactation

(b)Any immunocompromised state

(c)Patients with a history or physical exam suggestive of other causes of eosinophilia common in our settings-helminthic infection, DRESS(drug reaction with eosinophilia and systemic symptoms), bullous pemphigoid, chronic bullous disease of childhood , fungal infections, chronic pancreatitis, primary gastrointestinal eosinophilic disorders including inflammatory bowel disease, eosinophilic esophagitis, coeliac diseases, rheumatological disease-systemic lupus erythematosus, eosinophilic fasciitis (Shulman disease) , vasculitis - polyarteritis nodosa and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), rheumatoid arthritis and acute and chronic eosinophilic pneumonia (that includes Loeffler syndrome, sarcoidosis, allergic bronchopulmonary aspergillosis)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Classification of clinical characteristics of adult patients having AD into the following four subgroups as mentioned below <br/ ><br>1.High IgE & Eosinophilia <br/ ><br>2.Normal IgE & Eosinophilia <br/ ><br>3.High IgE and Normal Eosinophils <br/ ><br>4.Normal IgE and Normal Eosinophils <br/ ><br>Timepoint: 1.5 years <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
IL-4 levels in the different subgroupsTimepoint: 1.5 years
© Copyright 2025. All Rights Reserved by MedPath